Malaysia
Search
Sign In
Rheumatology
Top Medical News
Treatment with secukinumab 300 mg significantly improves symptoms of biologic-naïve patients with psoriatic arthritis (PsA) compared with placebo, results from the CHOICE study have shown.
Temporarily discontinuing methotrexate treatment for 1 week appears to induce satisfactory response to a seasonal influenza vaccine in patients with rheumatoid arthritis (RA), with a similar effect as a 2-week interruption schedule, according to a study.
Combination therapy with methotrexate (MTX) plus etanercept (ETN) results in more improved outcomes in men than in women with psoriatic arthritis (PsA) for minimal disease activity (MDA) and Psoriatic Arthritis Disease Activity Score (PASDAS), a study has shown.
Intake of supplemental vitamin D3 falls short of reducing the incidence of fractures among generally healthy midlife and older adults as compared with placebo, according to data from the Vitamin D and Omega-3 Trial (VITAL).
In the maintenance treatment of patients with lupus nephritis (LN), leflunomide is as effective and safe as azathioprine, according to a study.
Psoriatic arthritis (PsA) patients with moderate disease activity (MDA) at baseline who are treated with apremilast are more likely to achieve treatment targets than those with high disease activity (HDA), a recent study has shown.
Real-world patients with psoriatic arthritis (PsA) who received and remained on secukinumab treatment for 6 months has attained minimal disease activity (MDA) and shown improvements in clinical manifestations, patient-reported outcomes, and work productivity at follow-up, reveals a study. The results are consistent with findings from clinical trials.
Special Reports
Esflurbiprofen 40 mg transdermal patch
Upadacitinib 15 mg XR-FC tab
Romosozumab 105 mg/1.17 mL soln for inj
Conference Reports
In patients with juvenile idiopathic arthritis (JIA) with insufficient response to conventional synthetic (cs) or biologic (b) disease-modifying antirheumatic drugs (DMARDs), the JAK*1/2 selective inhibitor baricitinib reduced the frequency and delayed time to disease flares, according to a phase III trial presented at EULAR 2022.
Patients with psoriatic arthritis (PsA) with no prior exposure to biological disease-modifying antirheumatic drugs (bDMARDs) experience improvements in their condition when treated with bimekizumab, according to results of the phase III BE OPTIMAL trial.
Treatment with bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL-17A, significantly improved ASAS40* response rate in patients with either nonradiographic axial spondyloarthritis (nr-axSpA) or ankylosing spondylitis (AS**), according to two phase III studies presented at EULAR 2022.
The use of antihistamines was associated with reduced structural progression in knee osteoarthritis (OA), according to a post hoc analysis of two large phase III trials.
Treatment with upadacitinib improves disease activity, pain, function, and quality of life (QoL) in patients with non-radiographic axial spondyloarthritis (nr-axSpA) in a study touted as the first to evaluate a Janus kinase (JAK) inhibitor for this condition.
The monoclonal antibody sarilumab demonstrated significant efficacy in individuals with relapsing polymyalgia rheumatica (PMR), findings from the phase III SAPHYR trial have shown.
In the postintervention results of the VITAL* trial, vitamin D and marine omega-3 fatty acids (n-3 FAs) continued to demonstrate a protective effect against autoimmune diseases in older adults.
